NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
PRTA
Prothena Corporation plc
There isn't enough reported data to score PRTA yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
PRTA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
PRTA's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
PRTA PE Valuation
PRTA has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
PRTA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect PRTA's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over PRTA on earnings quality, reporting a profit while its opponent remains loss making.
PRTA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.47 | +$4.72 |
| Q2 2026 | -$0.83 | +$4.78 |
| Q1 2026 | -$2.81 | -$0.76 |
| Q4 2025 | -$4.53 | -$2.26 |
| Q3 2025 | -$5.19 | -$2.75 |
| Q2 2025 | -$5.61 | -$4.65 |
| Q1 2025 | -$2.05 | +$1.16 |
| Q4 2024 | -$2.27 | +$0.49 |
PRTA is still losing money, but far less than before: $0.47 per share over the past year, against $5.61 at its worst in mid-2025.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over PRTA on profitability, with a higher operating margin.
PRTA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $620K | -74% |
| Q2 2026 | $1M | -77% |
| Q1 2026 | $51.1M | +1706% |
| Q4 2025 | $21K | -99% |
| Q3 2025 | $2.4M | +149% |
| Q2 2025 | $4.4M | -97% |
| Q1 2025 | $2.8M | +5556% |
| Q4 2024 | $2.1M | +572% |
PRTA's revenue is growing: $620,000 last quarter, down 74% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3036% | -1369 points |
| Q2 2026 | -2089% | -175 points |
| Q1 2026 | 59% | +2378 points |
| Q4 2025 | -115252% | -112196 points |
| Q3 2025 | -1666% | +5191 points |
| Q2 2025 | -1914% | -1959 points |
| Q1 2025 | -2319% | +160737 points |
| Q4 2024 | -3057% | +21790 points |
PRTA's operating margin was −3036% last quarter, down 1369 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over PRTA on cash generation, producing positive trailing cash flow while its opponent burns cash.
PRTA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$12M | +$28.6M |
| Q2 2026 | -$25M | +$21.3M |
| Q1 2026 | $28.9M | +$82.2M |
| Q4 2025 | -$23.3M | +$24.5M |
| Q3 2025 | -$40.6M | +$4.6M |
| Q2 2025 | -$46.3M | -390% |
| Q1 2025 | -$53.4M | +$19.7M |
| Q4 2024 | -$47.8M | +$3.3M |
PRTA has burned cash in most quarters: −$31M over the past year, against −$188M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
PRTA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.4% | -708K shares |
| 1 year | -4.4% | -2.4M shares |
| 3 years | -11% | -6.6M shares |
| 5 years | +0.5% | +232K shares |
| Available history | +29% | +11.6M shares |
PRTA has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $4.3M |
| Q2 2026 | $15.6M |
| Q1 2026 | $6.9M |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
PRTA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2022 | -8.1x | Net Cash |
| Q4 2021 | -7.9x | Net Cash |
| Q3 2021 | -7.9x | Net Cash |
PRTA has more cash than debt.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
PRTA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.3 | Neutral |
| Stochastic | 20.5 | Neutral |
PRTA's weekly RSI is 44 (neutral) and its Stochastic is 21 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
PRTA PE vs Healthcare Sector
| Metric | PRTA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
PRTA has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over PRTA on trend strength, trading above more of its moving averages.
PRTA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.34 | 1.3% below |
| 20 week MA | $8.74 | 5.8% below |
| 50 week MA | $9.26 | 11% below |
| 100 week MA | $9.67 | 15% below |
| 200 week MA | $23.8 | 65% below |
PRTA is in a downtrend: it's below all five of its weekly moving averages, and 65% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
PRTA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.0 | $13.2 | -17% |
| 2021 | $13.2 | $48.4 | +265% |
| 2022 | $48.4 | $57.8 | +19% |
| 2023 | $57.8 | $36.3 | -37% |
| 2024 | $36.3 | $15.1 | -58% |
| 2025 | $15.1 | $9.54 | -37% |
| 2026 YTD | $9.54 | $8.23 | -14% |
PRTA has the edge over NVO on returns for 2026, with the stronger performance.